Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 11/20 | 0.37 |
| ▸ | CA2 | P00918 | 11/20 | 0.37 |
| ▸ | CA9 | Q16790 | 8/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA7 | P43166 | 3/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.36 |
| ▸ | CA3 | P07451 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | CA6 | P23280 | 2/20 | 0.36 |
| ▸ | CA5A | P35218 | 2/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12980423 | 0.96 | SMPD1 (0.42) | FDPSTP53SMPD1CA1CA2 | |
| Sulfuric Acid SCHEMBL17102633 | 0.85 | FDPS (0.47) | FDPSTP53SMPD1 | |
| SCHEMBL4407930 | 0.84 | CA1 (0.52) | FDPSSMPD1CA1CA2CA9 | |
| SCHEMBL4411973 | 0.84 | CA1 (0.47) | FDPSSMPD1CA1CA2CA9 | |
| SCHEMBL4407987 | 0.84 | CA1 (0.52) | FDPSSMPD1CA1CA2CA9 | |
| SCHEMBL18298283 | 0.84 | SMPD1 (0.45) | FDPSTP53SMPD1CA1CA2 | |
| SCHEMBL5922336 | 0.84 | SMPD1 (0.45) | FDPSTP53SMPD1CA1CA2 | |
| SCHEMBL29106637 | 0.84 | SMPD1 (0.45) | FDPSTP53SMPD1CA1CA2 | |
| SCHEMBL6245022 | 0.84 | SMPD1 (0.45) | FDPSTP53SMPD1CA1CA2 | |
| SCHEMBL6244623 | 0.84 | SMPD1 (0.45) | FDPSTP53SMPD1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395906-A1 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | CUSTOMARRAY INC (US) | 2021-12-23 | — | — | US | claimed |
| US-20130341561-A1 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | CUSTOMARRAY, INC. (US) | 2013-12-26 | — | — | US | claimed |
| US-7718579-B2 | Electrochemical deblocking using a hydrazine derivative | COMBIMATRIX CORPORATION (US) | 2010-05-18 | — | — | US | claimed |
| EP-1869061-A2 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | Combimatrix Corporation (US) | 2007-12-26 | — | — | EP | claimed |
| EP-1805206-A2 | ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE | Combimatrix Corporation (US) | 2007-07-11 | — | — | EP | claimed |
| US-20070034513-A1 | Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array | COMBIMATRIX CORPORATION | 2007-02-15 | — | — | US | claimed |
| WO-2006105037-A2 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | COMBIMATRIX CORPORATION (US) | 2006-10-05 | — | — | WO | claimed |
| WO-2006031814-A2 | ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE | COMBIMATRIX CORPORATION (US) | 2006-03-23 | — | — | WO | claimed |
| US-20060054511-A1 | Electrochemical deblocking using a hydrazine derivative | CUSTOMARRAY, INC. | 2006-03-16 | — | — | US | claimed |
| US-20240101999-A1 | HIGH EFFICIENCY, SMALL VOLUME NUCLEIC ACID SYNTHESIS | THERMO FISHER SCIENTIFIC GENEART GMBH (DE) | 2024-03-28 | — | — | US | disclosed |
| CN-115927293-A | Efficient small volume nucleic acid synthesis | 生命技术公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-107532129-B | Efficient small volume nucleic acid synthesis | 生命技术公司 | 2022-09-13 | — | — | CN | disclosed |
| EP-3557262-B1 | HIGH EFFICIENCY, SMALL VOLUME NUCLEIC ACID SYNTHESIS | LIFE TECHNOLOGIES CORP (US) | 2022-08-10 | — | — | EP | disclosed |
| US-20210395906-A1 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | CUSTOMARRAY INC (US) | 2021-12-23 | — | — | US | disclosed |
| EP-1869061-A2 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | Combimatrix Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1805206-A2 | ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE | Combimatrix Corporation (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070034513-A1 | Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array | COMBIMATRIX CORPORATION | 2007-02-15 | — | — | US | disclosed |
| WO-2006105037-A2 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | COMBIMATRIX CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006031814-A2 | ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE | COMBIMATRIX CORPORATION (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20060054511-A1 | Electrochemical deblocking using a hydrazine derivative | CUSTOMARRAY, INC. | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395906-A1 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | DNMT1, DNASE1, DNPEP | FDPS 3499/4885TP53 1987/4885SMPD1 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.